Biotech · Private company · Winchester, MA, US
Boston Immune Technologies And Therapeutics, Inc.
Track this companyFree. Adds Boston Immune Technologies And Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards5
- Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.Fiscal year 2026 · $990.2KNIH RePORTER 5R44AI179385-03 · fetched Nov 12, 2026
- Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.Fiscal year 2025 · $926.9KNIH RePORTER 4R44AI179385-02 · fetched Nov 12, 2026
- Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).Fiscal year 2025 · $2.4MNIH RePORTER 5R44CA265510-05 · fetched Nov 12, 2026
- Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).Fiscal year 2024 · $1.6MNIH RePORTER 2R44CA265510-04 · fetched Nov 12, 2026
- Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapyFiscal year 2024 · $777KNIH RePORTER 5R44CA265510-03 · fetched Nov 12, 2026